RKD

RKD Group Reinforces Client Experience, Purpose in Latest Leadership Moves

Retrieved on: 
Friday, March 8, 2024
SVP, Marketing, Growth, RKD, Human, Sconyers Bar-B-Que, Acceleration, Management

DALLAS, March 8, 2024 /PRNewswire/ -- RKD Group, the leading fundraising and marketing solutions provider to nonprofits in North America, announced its latest leadership moves.

Key Points: 
  • DALLAS, March 8, 2024 /PRNewswire/ -- RKD Group, the leading fundraising and marketing solutions provider to nonprofits in North America, announced its latest leadership moves.
  • "At our core, we are dedicated to amplifying and championing the missions of the clients we serve," said Chris Pritcher, CEO at RKD Group.
  • Dawn Beall, SVP of Client Engagement, has taken on a new role in RKD's client experience team, focused on enhancing the voice of the client throughout the entire client journey, from onboarding to proactive engagement and support.
  • Ellen Roeder has joined RKD as VP of Client Partnership, strengthening how RKD is transitioning clients from cooperative channel marketing to omnichannel donor experience.

RKD Group is Proud To Share The Latest Senior Leader Additions And Promotions

Retrieved on: 
Wednesday, January 31, 2024
Growth, Senior, RKD, AI, Acceleration, Mission, Strategy, Data science, Marketing, Side platform, Mouth, Culture, Management

DALLAS, Jan. 31, 2024 /PRNewswire/ -- RKD Group, the leading fundraising and marketing solutions provider to nonprofits in North America, announces additions and promotions to its leadership team.

Key Points: 
  • DALLAS, Jan. 31, 2024 /PRNewswire/ -- RKD Group, the leading fundraising and marketing solutions provider to nonprofits in North America, announces additions and promotions to its leadership team.
  • These additions emphasize RKD Group's commitment to client experience, transformational results and continued growth.
  • "The recognition of these three talented professionals underscores our commitment to our clients and giving them the best, most thoughtful, most forward-looking approach possible," said Chris Pritcher, CEO at RKD Group.
  • "I am thrilled to be a part of such a dynamic and diverse team with a deep commitment to nonprofit growth.

Vidya Chadaga Joins RKD Group as Executive Vice President of Products

Retrieved on: 
Thursday, May 11, 2023
IBM, Software as a service, Marketing, GE, SAP, Oracle, Vidya, RKD, ServiceMax, Management, Marketo, Adobe

DALLAS, May 11, 2023 /PRNewswire/ -- RKD Group, the leading fundraising and marketing solutions provider to nonprofits in North America, is thrilled to welcome Vidya Chadaga as Executive Vice President of Products.

Key Points: 
  • DALLAS, May 11, 2023 /PRNewswire/ -- RKD Group, the leading fundraising and marketing solutions provider to nonprofits in North America, is thrilled to welcome Vidya Chadaga as Executive Vice President of Products.
  • Chadaga is a skilled product strategist, technology expert and empathetic leader with more than two decades of experience in bringing innovative products to market.
  • "Vidya will be instrumental in our efforts to develop products that enable our nonprofit partners to reimagine their fundraising in this age of connection."
  • Chadaga will join RKD's executive committee, helping to build innovative solutions that solve the industry's biggest problems.

Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

Retrieved on: 
Monday, May 1, 2023
Kidney failure, CMA, Prevalence, Jay Traver, European Medicines Agency, New Drug Application, EGFR, CSL Vifor, Immunoglobulin A, EMA, Proteinuria, Kidney disease, Conditional, IgA nephropathy, Shanda, Patient, Focal segmental glomerulosclerosis, RKD, SAN, Kidney, Therapy, Caregiver, Pharmaceutical industry, Medical imaging, FSGS, Irbesartan

SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) --  Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), in focal segmental glomerulosclerosis (FSGS).

Key Points: 
  • SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) --  Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), in focal segmental glomerulosclerosis (FSGS).
  • After 108 weeks of treatment, sparsentan achieved a mean reduction in proteinuria from baseline of 50%, compared to 32% for irbesartan.
  • Results from the two-year analysis demonstrated that sparsentan was well-tolerated and has shown a comparable safety profile to irbesartan.
  • The secondary and topline exploratory endpoints, including renal outcomes, trended favorably for sparsentan in the study.

NephCure Joins Enon Tabernacle's Men's Health Initiative

Retrieved on: 
Wednesday, April 19, 2023
Blood pressure, University, Health education, APOL1, Urine, Kidney disease, Cholesterol, African Americans, Pastor, Video, Boehringer Ingelheim, RKD, Risk, Cancer, Platinum Partners, Health, FDA, Therapy, Labcorp, Mental health, Men's Health, Mallinckrodt, Prostate cancer, Pharmaceutical industry, Church

KING OF PRUSSIA, Pa., April 19, 2023 /PRNewswire/ -- NephCure, a nonprofit focused on finding better treatments and a cure for rare kidney disease (RKD), is partnering with Enon Tabernacle Baptist Church as they host their 12th annual "Men Know Your Numbers" health education and screening event on April 22 from 8 a.m. to 6 p.m ET.

Key Points: 
  • During the event, the Church, located at 2800 W. Cheltenham Ave. in Mount Airy, transforms their house of worship into a men's health and wellness clinic.
  • This year, NephCure is working with the University of Pennsylvania chapter of the Kidney Disease Screening and Awareness Program to offer on-site urine screening for kidney disease.
  • The event with Enon Tabernacle also serves as the kick-off of NephCure's RKD Screening Campaign, an ongoing effort to provide kidney disease education and screening opportunities in targeted locations nationwide.
  • NephCure is proud to recognize Travere Therapeutics as a Platinum Partner of NephCure's RKD Screening Campaign.

Interim Analysis of the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Presented by Travere Therapeutics at NKF Spring Clinical Meetings

Retrieved on: 
Thursday, April 13, 2023
CT, Kidney failure, Heart Protection Study, Immunoglobulin A, Proteinuria, IgA nephropathy, Nephrology, Patient, RKD, Division, NKF, National Kidney Foundation, University Center, Therapy, PROTECT, Kidney disease, Safety, Pharmaceutical industry, Irbesartan

Data demonstrates a significant and clinically meaningful anti-proteinuric effect of Sparsentan compared to Irbesartan.

Key Points: 
  • Data demonstrates a significant and clinically meaningful anti-proteinuric effect of Sparsentan compared to Irbesartan.
  • "The data also highlight a consistent treatment effect across patient populations, regardless of age, race, gender, clinical characteristics, and concomitant medications."
  • Data from the study were recently published in The Lancet and announced by Travere Therapeutics.
  • Thousands of kidney care professionals will attend the Spring Clinical Meetings in-person and virtually.

NephCure Unveils New Branding Reflecting Organization's Focus on Rare Kidney Disease

Retrieved on: 
Friday, March 31, 2023
Volunteering, Nephrotic syndrome, FSGS, Research, Director of communications, Kidney disease, Patient, RKD, Kidney, Growth, Government, Health, Caregiver, Pharmaceutical industry, Dietary supplement, IgA nephropathy

KING OF PRUSSIA, Pa., March 31, 2023 /PRNewswire/ -- NephCure, formerly NephCure Kidney International, announced Friday a new visual and written brand more distinctly centered around the rare kidney disease (RKD) community they serve. With nearly a year of research and development behind it, this new brand more accurately reflects the nonprofit's unique position in the RKD space, as well as the explosive growth and transformation the RKD field has seen over the past several years.

Key Points: 
  • KING OF PRUSSIA, Pa., March 31, 2023 /PRNewswire/ -- NephCure, formerly NephCure Kidney International, announced Friday a new visual and written brand more distinctly centered around the rare kidney disease (RKD) community they serve.
  • NephCure, a nonprofit focused on finding better treatments for rare kidney disease, updates its brand identity.
  • Unique among the major kidney organizations, NephCure is squarely focused on nephrotic syndrome, FSGS, IgAN, and other rare, protein-spilling kidney diseases.
  • New Tagline: "For rare kidney disease" reflects NephCure's distinct focus on RKD, as well as their passion and focus to continuously strive to find a cure.

Bart Lillie Joins RKD Group as Vice President of Strategic Engagement

Retrieved on: 
Thursday, March 30, 2023
Organization, SVP, RKD, Culture, Marketing, US-China strategic engagement

DALLAS, March 30, 2023 /PRNewswire/ -- RKD Group, the leading fundraising and marketing solutions provider to nonprofits in North America, is thrilled to welcome Bart Lillie as Vice President of Strategic Engagement.

Key Points: 
  • DALLAS, March 30, 2023 /PRNewswire/ -- RKD Group, the leading fundraising and marketing solutions provider to nonprofits in North America, is thrilled to welcome Bart Lillie as Vice President of Strategic Engagement.
  • Lillie comes to RKD with three decades of experience in nonprofit storytelling, analytics and relationship management.
  • "Bart is a dynamic advocate for nonprofits," SVP of Strategic Growth Lori Read said.
  • At RKD, we're constantly challenging the status quo, and I know Bart will be a major contributor in helping us revolutionize the future for our clients."

Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

Retrieved on: 
Friday, February 17, 2023
Caregiver, PROTECT, Irbesartan, Immunoglobulin A, Kidney failure, University Center, Hope, Safety, ARB, ACE, UPCR, Proteinuria, Patient, Division, HIV disease progression rates, Heart Protection Study, Clinical trial, Nephrology, Food, Therapy, Risk, Hypertension, Erosion (morphology), Kidney disease, Disease, RKD, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mevalonate pathway, Angiotensin, MD, Pharmaceutical industry, IgA nephropathy

SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to FILSPARI™ (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.

Key Points: 
  • This indication is granted under accelerated approval based on reduction in proteinuria.
  • “The accelerated approval of FILSPARI is a significant milestone on our path to advancing a transformative treatment for the IgA nephropathy community,” said Eric Dube, Ph.D., president and chief executive officer, Travere Therapeutics.
  • “The approval of this innovative treatment is founded in data from the largest head-to-head Phase 3 clinical trial in IgA nephropathy.
  • ET to discuss the FDA accelerated approval and launch of FILSPARI.

RKD Group Selects Chris Pritcher as New CEO

Retrieved on: 
Thursday, January 12, 2023
Creative, Merkle Inc., Royall, RKD, Marketing, Data Analytics Acceleration Library, Growth, Creativity, Acceleration, Royal Company of Archers, Management, Merkle

DALLAS, Jan. 12, 2023 /PRNewswire/ -- RKD, the leading fundraising and marketing solutions provider to nonprofits in North America, has appointed Chris Pritcher as its next Chief Executive Officer.

Key Points: 
  • DALLAS, Jan. 12, 2023 /PRNewswire/ -- RKD, the leading fundraising and marketing solutions provider to nonprofits in North America, has appointed Chris Pritcher as its next Chief Executive Officer.
  • "Chris is uniquely qualified to lead RKD," Kersten said.
  • Chris' perspectives will be a strong asset as we build on our success into the next chapter of charitable giving."
  • I am humbled and excited to join this company, work closely with Tim, the board and the entire RKD team—to listen, learn and collectively build solutions that help nonprofits succeed," said Pritcher.